FY2024 EPS Estimates for Humacyte Decreased by HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Humacyte in a research report issued on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn ($1.36) per share for the year, down from their prior forecast of ($1.28). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Humacyte’s FY2025 earnings at ($0.77) EPS.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04).

A number of other brokerages have also recently commented on HUMA. BTIG Research restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. Benchmark reiterated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. TD Cowen reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $11.00.

Humacyte Stock Performance

Shares of HUMA stock opened at $4.84 on Friday. The stock has a market capitalization of $577.65 million, a P/E ratio of -3.66 and a beta of 1.47. The company has a current ratio of 1.10, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. The firm’s 50 day moving average is $5.44 and its 200 day moving average is $6.17. Humacyte has a 12 month low of $2.35 and a 12 month high of $9.97.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in the company. Endowment Wealth Management Inc. grew its holdings in Humacyte by 3.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after acquiring an additional 3,000 shares during the last quarter. nVerses Capital LLC bought a new stake in Humacyte in the 2nd quarter worth $28,000. Private Advisor Group LLC grew its holdings in Humacyte by 1.8% in the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after acquiring an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Humacyte by 32.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after purchasing an additional 8,557 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Humacyte by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after purchasing an additional 8,965 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

Insider Activity at Humacyte

In related news, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. This trade represents a 5.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Laura E. Niklason sold 277,090 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the transaction, the chief executive officer now directly owns 4,029,374 shares in the company, valued at approximately $26,070,049.78. This represents a 6.43 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. Insiders own 11.20% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.